e-therapeutics plc announced the expansion of its Scientific Advisory Board with the appointment of Bill Harte and Professor John Mattick. The appointments follow the establishment of the SAB in May of 2020 with the initial appointment of Paul Burke as Chair following the Company's expansion into RNA interference (RNAi) as a therapeutic modality to pursue drug discovery outcomes. Dr. Bill Harte is a pharmaceutical veteran and serial entrepreneur with more than 30 years in both research and executive positions. He currently serves as the Chief Translational Officer at the Case Western Reserve University School of Medicine advising and translating preclinical programs into patients.